SciSparc's New Patent Application in Collaboration for Depression Treatment
SciSparc Ltd. (Nasdaq: SPRC), a leader in clinical-stage pharmaceutical developments, has recently announced an exciting advancement in their collaboration with NeuroThera Labs Inc. and Clearmind Medicine Inc. This partnership has resulted in the submission of an Israeli patent application for a novel treatment targeting depression. The innovative combination involves 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA), offering fresh hope in the fight against this pervasive condition.
The Urgency of Addressing Depression
Current Global Statistics
An alarming report from the World Health Organization indicates that major depressive disorder impacts around 332 million individuals worldwide. This staggering statistic reflects approximately 5.7% of adults globally, highlighting the urgent need for effective treatments. The condition disproportionately affects women, with a prevalence rate of 6.9% compared to 4.6% for men. Depression remains a leading cause of disability, significantly contributing to the global burden of disease.
Innovation Through Collaboration
The recent patent application is a significant step in expanding the joint intellectual property portfolio of SciSparc and its collaborators. This application is the result of their ongoing alliance, which has already resulted in 13 patents focusing on the benefits and formulations involving MEAI and PEA. These patents address various conditions, from alcohol use disorder to cocaine addiction, as well as obesity and weight management. Notably, the preclinical success of MEAI in lessening addictive behaviors while maintaining natural reward pathways offers a promising outlook for those struggling with depression.
About SciSparc Ltd.
Focus on Advanced Therapeutics
Established as a forerunner in cannabinoid pharmaceuticals, SciSparc Ltd. engages through its majority-owned subsidiary Neurothera Labs Inc. to cultivate a dynamic portfolio of clinical-stage pharmaceutical innovations. The company is dedicated to advancing treatments for a variety of conditions, utilizing THC and non-psychoactive CBD in its formulations. Current programs include SCI-110, targeting Tourette syndrome, and SCI-210, focused on addressing challenges associated with autism spectrum disorder and status epilepticus.
Commitment to Mental Health
SciSparc's mission not only involves enhancing physical well-being but also aims to tackle significant mental health challenges. Through innovative therapies like 5-methoxy-2-aminoindane, the company is positioning itself at the forefront of neurotherapeutics, striving to provide effective remedies for depression and related disorders.
Neurothera Labs Inc. Overview
Neurothera Labs Inc. specializes in developing groundbreaking therapeutics to address disorders affecting the central nervous system and other critical health issues. The company is committed to leveraging collaborations and innovative combinations to create impactful therapeutic solutions for patients in need.
Frequently Asked Questions
What is the significance of the new patent application?
The patent application represents a promising advancement in developing a new therapy for depression using a unique combination of MEAI and PEA.
How prevalent is depression globally?
Depression affects approximately 332 million people worldwide, which is about 5.7% of the adult population, making it a major health concern.
What conditions are targeted by the joint intellectual property?
The portfolio targets several conditions, including depression, alcohol use disorder, cocaine addiction, and obesity.
What does SciSparc focus on?
SciSparc is dedicated to developing innovative cannabinoid-based pharmaceuticals aimed at treating various CNS disorders.
Who can benefit from the therapies developed by SciSparc?
Patients struggling with conditions such as depression, Tourette syndrome, and autism spectrum disorder may benefit from SciSparc's innovative therapies.
